The brain microenvironment imposes a particularly intense selective pressure on metastasis-initiating cells, but successful metastases bypass this control through mechanisms that are poorly understood. Reactive astrocytes are key components of this microenvironment that confine brain metastasis without infiltrating the lesion. Here, we describe that brain metastatic cells induce and maintain the co-option of a pro-metastatic program driven by signal transducer and activator of transcription 3 (STAT3) in a subpopulation of reactive astrocytes surrounding metastatic lesions. These reactive astrocytes benefit metastatic cells by their modulatory effect on the innate and acquired immune system. In patients, active STAT3 in reactive astrocytes correlates with reduced survival from diagnosis of intracranial metastases. Blocking STAT3 signaling in reactive astrocytes reduces experimental brain metastasis from different primary tumor sources, even at advanced stages of colonization. We also show that a safe and orally bioavailable treatment that inhibits STAT3 exhibits significant antitumor effects in patients with advanced systemic disease that included brain metastasis. Responses to this therapy were notable in the central nervous system, where several complete responses were achieved. Given that brain metastasis causes substantial morbidity and mortality, our results identify a novel treatment for increasing survival in patients with secondary brain tumors.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Data availability

All published non-commercial reagents can be made available upon request to the corresponding author. The proteomics data are available at PRIDE (PXD008956).

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

  • 19 June 2018

    In the version of this article originally published, the names of three authors were incorrect. The authors were listed as “Coral Fustero-Torres”, “Elena Pineiro” and “Melchor Sánchez-Martínez”. Their respective names are “Coral Fustero-Torre”, “Elena Piñeiro-Yáñez” and “Melchor Sanchez-Martinez”. The errors have been corrected in the print, HTML and PDF versions of this article.


  1. 1.

    Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116–122 (2010).

  2. 2.

    Valiente, M. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002–1016 (2014).

  3. 3.

    Sevenich, L. et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat. Cell Biol. 16, 876–888 (2014).

  4. 4.

    Sofroniew, M. V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638–647 (2009).

  5. 5.

    Chen, Q. et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533, 493–498 (2016).

  6. 6.

    Anderson, M. A., Ao, Y. & Sofroniew, M. V. Heterogeneity of reactive astrocytes. Neurosci. Lett. 565, 23–29 (2014).

  7. 7.

    Okada, S. et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat. Med. 12, 829–834 (2006).

  8. 8.

    Wanner, I. B. et al. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. J. Neurosci. 33, 12870–12886 (2013).

  9. 9.

    LeComte, M. D., Shimada, I. S., Sherwin, C. & Spees, J. L. Notch1–STAT3–ETBR signaling axis controls reactive astrocyte proliferation after brain injury. Proc. Natl Acad. Sci. USA 112, 8726–8731 (2015).

  10. 10.

    Ben Haim, L. et al. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer’s and Huntington’s diseases. J. Neurosci. 35, 2817–2829 (2015).

  11. 11.

    Jee, Y., Kim, G., Tanuma, N. & Matsumoto, Y. STAT expression and localization in the central nervous system during autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 114, 40–47 (2001).

  12. 12.

    Lee, H.-T. et al. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget 6, 10016–10029 (2015).

  13. 13.

    Kong, L.-Y. et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin. Cancer Res. 14, 5759–5768 (2008).

  14. 14.

    Singh, M. et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget 6, 27461–27477 (2015).

  15. 15.

    Hatiboglu, M. A. et al. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int. J. Cancer 131, 8–17 (2012).

  16. 16.

    Jones, L. M. et al. STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. Cancer Res. 76, 1416–1428 (2016).

  17. 17.

    Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48–54 (2004).

  18. 18.

    Berghoff, A. S. et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5, e1057388 (2016).

  19. 19.

    Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326–341 (2017).

  20. 20.

    Ganat, Y. M. et al. Early postnatal astroglial cells produce multilineage precursors and neural stem cells in vivo. J. Neurosci. 26, 8609–8621 (2006).

  21. 21.

    Alonzi, T. et al. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell. Biol. 21, 1621–1632 (2001).

  22. 22.

    Chuang, H.-N. et al. Carcinoma cells misuse the host tissue damage response to invade the brain. Glia 61, 1331–1346 (2013).

  23. 23.

    Iwamaru, A. et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26, 2435–2444 (2007).

  24. 24.

    Steinman, R. A., Wentzel, A., Lu, Y., Stehle, C. & Grandis, J. R. Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by Cdk2. Oncogene 22, 3608–3615 (2003).

  25. 25.

    Bachoo, R. M. et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269–277 (2002).

  26. 26.

    Anderson, M. A. et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195–200 (2016).

  27. 27.

    Drukker, M. & Benvenisty, N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol. 22, 136–141 (2004).

  28. 28.

    Aurora, A. B. & Olson, E. N. Immune modulation of stem cells and regeneration. Cell Stem Cell 15, 14–25 (2014).

  29. 29.

    Dubeykovskaya, Z. et al. Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. Nat. Commun. 7, 10517 (2016).

  30. 30.

    Cho, J.-H. et al. Unique features of naive CD8+ T cell activation by IL-2. J. Immunol. 191, 5559–5573 (2013).

  31. 31.

    Rosenblum, M. D., Way, S. S. & Abbas, A. K. Regulatory T cell memory. Nat. Rev. Immunol. 16, 90–101 (2016).

  32. 32.

    Kaur, S. et al. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. J. Immunol. 193, 3914–3924 (2014).

  33. 33.

    Ashraf, M. I. et al. Exogenous lipocalin 2 ameliorates acute rejection in a mouse model of renal transplantation. Am. J. Transplant. 16, 808–820 (2016).

  34. 34.

    Thorne, M., Moore, C. S. & Robertson, G. S. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J. Neuroimmunol. 211, 92–100 (2009).

  35. 35.

    Sorokin, L. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 10, 712–723 (2010).

  36. 36.

    Wölfle, S. J. et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol. 41, 413–424 (2011).

  37. 37.

    Ghoochani, A. et al. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene 35, 6246–6261 (2016).

  38. 38.

    Leng, L. et al. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467–1476 (2003).

  39. 39.

    Becker-Herman, S., Arie, G., Medvedovsky, H., Kerem, A. & Shachar, I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol. Biol. Cell 16, 5061–5069 (2005).

  40. 40.

    Gil-Yarom, N. et al. CD74 is a novel transcription regulator. Proc. Natl Acad. Sci. USA 114, 562–567 (2017).

  41. 41.

    Cohen, S. et al. The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74. J. Immunol. 188, 259–269 (2012).

  42. 42.

    Nguyen, D. X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51–62 (2009).

  43. 43.

    Cho, Y. et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc. Natl Acad. Sci. USA 107, 11313–11318 (2010).

  44. 44.

    Bosch-Barrera, J. et al. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget 7, 32006–32014 (2016).

  45. 45.

    Lee, Y., Park, H. R., Chun, H. J. & Lee, J. Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease via mitochondrial stabilization. J. Neurosci. Res. 93, 755–765 (2015).

  46. 46.

    Bosch-Barrera, J. & Menendez, J. A. Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy. Cancer Treat. Rev. 41, 540–546 (2015).

  47. 47.

    Bromberg, J. F. et al. Stat3 as an oncogene. Cell 98, 295–303 (1999).

  48. 48.

    Sperduto, P. W. et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 3, 827–831 (2017).

  49. 49.

    Kumthekar, P. et al. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J. Neurooncol. 112, 247–255 (2013).

  50. 50.

    Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164–1177 (2015).

  51. 51.

    Paik, P. K. et al. Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov. 5, 610–621 (2015).

  52. 52.

    Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290.e17 (2017).

  53. 53.

    Masgrau, R., Guaza, C., Ransohoff, R. M. & Galea, E. Should we stop saying “glia” and “neuroinflammation”? Trends Mol. Med. 23, 486–500 (2017).

  54. 54.

    Zhang, L. et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527, 100–104 (2015).

  55. 55.

    Kim, S.-J. et al. Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice. Clin. Cancer Res. 21, 4630–4641 (2015).

  56. 56.

    Neman, J. et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc. Natl Acad. Sci. USA 111, 984–989 (2014).

  57. 57.

    Louie, E. et al. Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene 32, 4064–4077 (2013).

  58. 58.

    Lyle, L. T. et al. Alterations in pericyte subpopulations are associated with elevated blood–tumor barrier permeability in experimental brain metastasis of breast cancer. Clin. Cancer Res. 22, 5287–5299 (2016).

  59. 59.

    Schwartz, H. et al. Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation. Cancer Res. 76, 4359–4371 (2016).

  60. 60.

    Valiente, M. et al. The evolving landscape of brain metastasis. Trends Cancer 4, 176–196 (2018).

  61. 61.

    Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005–1009 (2009).

  62. 62.

    Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60 (2016).

  63. 63.

    Campeau, E. et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE 4, e6529 (2009).

  64. 64.

    Schildge, S., Bohrer, C., Beck, K. & Schachtrup, C. Isolation and culture of mouse cortical astrocytes. J. Vis. Exp. 71, 50079 (2013).

  65. 65.

    Hillion, J. et al. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res. 68, 10121–10127 (2008).

  66. 66.

    Lin, N. U. et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 16, e270–e278 (2015).

  67. 67.

    Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).

Download references


We want to thank the CNIO Core Facilities for their excellent assistance. We also thank F.X. Real, O. Marín, M. Serrano, O. Fernandez-Capetillo and M. Soengas for critically reading the manuscript, P. Bos for advice with CD8+ T cell experiments, J. Massagué (MSKCC) for the BrM cell lines, MEDA for Legasil, M. A. Pérez (University of Copenhagen), H. Peinado (CNIO), M. Soengas (CNIO) and M. Squatrito (CNIO) for reagents. This work was supported by MINECO grants MINECO-Retos SAF2014-57243-R (M.V.), MINECO-Europa Excelencia SAF2015-62547-ERC (M.V.), FERO Grant for Research in Oncology (M.V.), Melanoma Research Alliance Young Investigator Award (M.V.), AECC Coordinated Translational Groups (M.V., E.M.-S. and S.R.y.C), SEOM (J.B.-B.), Pfizer WI190764 (J.B.-B.), Meda Pharma (J.B.-B.), Armangué Family Fund (J.A.M. and J.B.-B.), La Caixa-Severo Ochoa International PhD Program Fellowship (L.Z.), FCT PhD Fellowship SFRH/BD/100089/2014 (C.M.), the Fulbright Program (W.B.). M.V. is a Ramón y Cajal Investigator (RYC-2013-13365). This work is dedicated to the memory of María Jesús Cortés Garín.

Author information

Author notes

    • David Wasilewski

    Present address: Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    • Laura Doglio

    Present address: Centre for Developmental Neurobiology, King’s College London, London, UK


  1. Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

    • Neibla Priego
    • , Lucía Zhu
    • , Cátia Monteiro
    • , Manon Mulders
    • , David Wasilewski
    • , Wendy Bindeman
    • , Laura Doglio
    • , Liliana Martínez
    •  & Manuel Valiente
  2. Pathology Department, Vall d’Hebron Hospital, Barcelona, Spain

    • Elena Martínez-Saez
    •  & Santiago Ramón y Cajal
  3. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain

    • Elena Martínez-Saez
    •  & Santiago Ramón y Cajal
  4. Confocal Microscopy Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

    • Diego Megías
  5. Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain

    • Elena Hernández-Encinas
    •  & Carmen Blanco-Aparicio
  6. Flow Cytometry Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

    • Lola Martínez
  7. ProteoRed-ISCIII. Proteomics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

    • Eduardo Zarzuela
    •  & Javier Muñoz
  8. Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

    • Coral Fustero-Torre
    •  & Elena Piñeiro-Yáñez
  9. Neuropathology Unit, Hospital Universitario 12 de Octubre Research Institute, Madrid, Spain

    • Aurelio Hernández-Laín
  10. Medical Sciences Department, Division of Pathology, University and City of Health and Science University Hospital of Turin, Turin, Italy

    • Luca Bertero
  11. Molecular Biotechnology Centre, University of Turin, Turin, Italy

    • Valeria Poli
  12. Mind the Byte, Barcelona, Spain

    • Melchor Sanchez-Martinez
  13. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain

    • Javier A. Menendez
  14. Molecular Oncology Group, Girona Biomedical Research Institute (IDIBGI), Girona, Spain

    • Javier A. Menendez
    •  & Joaquim Bosch-Barrera
  15. Neuro-Oncology Department, University and City of Health and Science University Hospital of Turin, Turin, Italy

    • Riccardo Soffietti
  16. Department of Medical Sciences, Medical School, University of Girona, Girona, Spain

    • Joaquim Bosch-Barrera
  17. Catalan Institute of Oncology (ICO), Dr. Josep Trueta University Hospital, Girona, Spain

    • Joaquim Bosch-Barrera


  1. Search for Neibla Priego in:

  2. Search for Lucía Zhu in:

  3. Search for Cátia Monteiro in:

  4. Search for Manon Mulders in:

  5. Search for David Wasilewski in:

  6. Search for Wendy Bindeman in:

  7. Search for Laura Doglio in:

  8. Search for Liliana Martínez in:

  9. Search for Elena Martínez-Saez in:

  10. Search for Santiago Ramón y Cajal in:

  11. Search for Diego Megías in:

  12. Search for Elena Hernández-Encinas in:

  13. Search for Carmen Blanco-Aparicio in:

  14. Search for Lola Martínez in:

  15. Search for Eduardo Zarzuela in:

  16. Search for Javier Muñoz in:

  17. Search for Coral Fustero-Torre in:

  18. Search for Elena Piñeiro-Yáñez in:

  19. Search for Aurelio Hernández-Laín in:

  20. Search for Luca Bertero in:

  21. Search for Valeria Poli in:

  22. Search for Melchor Sanchez-Martinez in:

  23. Search for Javier A. Menendez in:

  24. Search for Riccardo Soffietti in:

  25. Search for Joaquim Bosch-Barrera in:

  26. Search for Manuel Valiente in:


N.P. and M.V. designed and performed the experiments, analyzed the data and wrote the manuscript. L.Z., C.M., M.M., D.W., W.B., L.D. and Liliana M. performed the experiments and analyzed the data. E.H.-E., C.B.-A. and L.Z. performed the pharmacokinetic experiments and analyzed the data. E.Z., J.M. and N.P. performed the proteomic experiments and analyzed the data. C.F.-T. and E.P. performed the bioinformatics analysis. V.P. provided the Stat3loxP/loxP mice. M.S.-M. and J.A.M. performed the in silico modeling. J.B.-B. performed the clinical study with Legasil. E.M.-S., S.R.y.C., A.H.-L., L.B. and R.S. provided the human samples and determined suitability for study. E.M.-S. scored the human samples. D.M. provided technical support with microscopy. Lola M. provided technical support with flow cytometry.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Manuel Valiente.

Supplementary information

  1. Supplementary Text and Figures

    Supplementary Figures 1–5 and Supplementary Tables 1–6

  2. Reporting Summary

About this article

Publication history





Further reading